Cuproptosis‐associated lncRNA impact prognosis in patients with non‐small cell lung cancer co‐infected with COVID ‐19
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70059 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Dushu Lake Ho…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, RNA, Long Noncoding, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Science and Technology Planning Project, Jiangsu Province Special Program of Medical Science.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) patients infected with COVID‐19 experience much worse prognosis. However, the specific mechanisms behind this phenomenon remain unclear. We conducted a multicentre study, collecting surgical tissue samples from a total of 36 NSCLC patients across three centres to analyse. Among the 36 lung cancer patients, 9 were infected with COVID‐19. COVID‐19 infection (HR = 21.62 [1.58, 296.06], p = 0.021) was an independent risk factor of progression‐free survival (PFS). Analysis of RNA‐seq data of these cancer tissues demonstrated significantly higher expression levels of cuproptosis‐associated genes in COVID‐19‐infected lung cancer patients. Using Lasso regression and Cox regression analysis, we identified 12 long noncoding RNAs (lncRNA) regulating cuproptosis. A score based on these lncRNA were used to divide patients into high‐risk and low‐risk groups. The results showed that the high‐risk group had lower overall survival and PFS compared to the low‐risk group. Furthermore, Tumor Immune Dysfunction and Exclusion (TIDE) database revealed that the high‐risk group benefited more from immunotherapy. Drug sensitivity analysis identified cetuximab and gefitinib as potentially effective treatments for the high‐risk group. Cuproptosis plays a significant role NSCLC patients infected with COVID‐19. Promisingly, cetuximab and gefitinib have shown potential effectiveness for managing these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Dushu Lake Hospital Affiliated to Soochow University, Medical Centre of Soochow Uni…
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Dushu Lake Hospital Affiliated to Soochow University, Medical Centre of Soochow University, Suzhou, Jiang…
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China.
- Department of Medical Oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Department of Thoracic Surgery, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Junhong Jiang
Förderung
- Suzhou Science and Technology Planning Project
- Jiangsu Province Special Program of Medical Science
Zitieren
APA
Li, J., Wang, N., Mao, G., Wang, J., Xiang, M., Zhang, H., Zeng, D., Ma, H., & Jiang, J. (2024). Cuproptosis‐associated lncRNA impact prognosis in patients with non‐small cell lung cancer co‐infected with COVID ‐19. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70059
Vancouver
Li J, Wang N, Mao G, Wang J, Xiang M, Zhang H, et al. Cuproptosis‐associated lncRNA impact prognosis in patients with non‐small cell lung cancer co‐infected with COVID ‐19. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70059
BibTeX
@article{Li2024,
author = {Li, Jing and Wang, Nan and Mao, Guocai and Wang, Jiantang and Xiang, Mengqi and Zhang, Huachuan and Zeng, Daxiong and Ma, Haitao and Jiang, Junhong},
title = {Cuproptosis‐associated lncRNA impact prognosis in patients with non‐small cell lung cancer co‐infected with COVID ‐19},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70059}
}
EUVIMED